CA-DENODO
11.3.2020 08:02:06 CET | Business Wire | Press release
Denodo , the leader in data virtualization, today announced that it has been recognized in the Gartner Peer Insights “Voice of the Customer”: Data Integration Tools, 4 December, 2019 as the only data integration product that was recommended by 100 percent of the reviewers. With an overall rating of 4.5 out of 5, Denodo received the second highest ranking of the fifteen eligible vendors for Evaluation and Contracting. It also rated 4.5 out of 5 for Product Capabilities and Integration and Deployment respectively and 4.4 out of 5 for Service and Support*. The complete list of Gartner Peer Insights user reviews and ratings published within the twelve months ending 31st October 2019, can be seen here .
According to Gartner, “The market for data integration tools includes vendors that offer software products to enable the construction and implementation of data access and data delivery infrastructure for a variety of data integration scenarios. For vendors, the demand for traditional data integration capabilities alongside the demand for innovative solutions requires robust, consistent delivery of highly developed solutions. Similarly, data integration tools interoperate and integrate with master data tools, data governance tools and data quality tools.”
Sample and actual reviews from customers include:
- “The technology from Denodo is mature, stable and solid, with new desirable features being added quarterly. The pricing model is totally easy and logical (priced per production CPU cores, no other fees other than their optional but superb professional services).” The full review can be seen here .
- “Data abstraction, federation, and caching capabilities have worked extremely well. The quality of interactions with the Denodo staff from Sales to Support have been top-notch. The ability to influence the product roadmap has provided a path to help ensure that desired features/capabilities are implemented.” The full review can be seen here .
Denodo was also recognized for the second year as a Challenger in the 2019 Gartner Magic Quadrant for Data Integration Tools placing furthest in completeness of vision in the Challengers quadrant this year. This report recognizes that the market for data integration tools “continues to evolve and is supported by strong levels of adoption.”
“We are absolutely thrilled to receive such high ratings from by our customers as we believe it speaks to the fact that our end customers are extremely satisfied with our product, services and support,” said Ravi Shankar, SVP and CMO, Denodo. “We are constantly striving to ensure our data virtualization platform delivers tremendous value and sincerely thank our customers for their continued confidence and support.”
*Overall Rating and Willingness to Recommend are based on 35 total reviews within one-year period ending October 31, 2019; Product Capabilities is based on 35 reviews; Evaluation and Contracting is based on 27 reviews; Integration and Deployment is based on 33 reviews; and Service & Support is based on 35 reviews.
Sources: Gartner, Gartner Peer Insights ‘Voice of the Customer’: Data Integration Tools, Peer Contributors, 4 December 2019. Gartner, Magic Quadrant for Data Integration Tools, Ehtisham Zaidi, Eric Thoo, Nick Heudecker, 1 August 2019.
About Peer Insights
Peer Insights is an online platform of ratings and reviews of IT software and services that are written and read by IT professionals and technology decision-makers. The goal is to help IT leaders make more insightful purchase decisions and help technology providers improve their products by receiving objective, unbiased feedback from their customers. Gartner Peer Insights includes more than 70,000 verified reviews in more than 200 markets. For more information, please visit www.gartner.com .
Required Disclaimers
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights reviews constitute the subjective opinions of individual end users based on their own experiences and do not represent the views of Gartner or its affiliates.
Please Tweet: #datavirtualization expert @denodo Receives 100% ‘Willingness to Recommend’ by Reviewers in 2020 @Gartner_inc “Voice of the Customer”: Data Integration Tools. (https://buff.ly/38DBaxg )
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom